Dutch group recommends restrictive antibiotic use in COVID patients
Based on available evidence and antibiotic stewardship principles, a committee of Dutch clinicians and researchers is recommending restrictive use of antibiotics in COVID-19 patients, according to guidelines published yesterday in Clinical Microbiology and Infection.
With the intention of developing evidence-based recommendations for the use of antibiotics in patients with a respiratory infection and suspected or confirmed COVID-19, the Dutch Working Party on Antibiotic Policy conducted a review and analysis of literature on COVID-19 and bacterial co-infections and secondary infections.
They set out to answer four key questions about the risk of bacterial pneumonia in patients with suspected or confirmed COVID-19, the causative bacterial species, the optimal approach to diagnosing or refuting bacterial pneumonia, and the optimal antibiotic choice.
The committee found that bacterial co-infection upon admission occurred in 3.5% of COVID-19 patients, while bacterial secondary infections during hospitalization occurred in up to 15% of patients. But not enough evidence was available to answer the other questions.
The committee agreed that clinicians should always assess the risk of a bacterial infection in patients with suspected COVID-19 and that antibiotic therapy should be considered if the clinician has a high suspicion of bacterial co-infection in a patient with radiologic findings and/or inflammatory markers compatible with bacterial co-infection.
But they also said maximum efforts should be undertaken to obtain sputum and blood culture samples and conduct pneumococcal urinary antigen testing and suggested that antibiotics be stopped if results show no signs of bacterial pathogens after 48 hours.
The committee recommended an antibiotic treatment duration of 5 days in patients with COVID-19 and suspected bacterial respiratory infection, contingent upon improvement in signs, symptoms, and inflammatory markers.
The committee says larger, prospective studies on the epidemiology of bacterial co-infections and secondary infections in COVID-19 patients are needed to confirm their conclusions.
Sep 30 Clin Microbiol Infect study
Study: California ASP mandate associated with C diff reduction, MRSA rise
A study today in Infection Control & Hospital Epidemiology shows that California's antimicrobial stewardship program (ASP) mandate was associated with a decrease in Clostridium difficile infection (CDI) rates and an increase in methicillin-resistant Staphylococcus aureus (MRSA) rates in acute care hospitals.
To evaluate the impact of a 2014 law that required acute care hospitals in California to adopt and implement an ASP, researchers analyzed hospital-level data covering 2013 through 2017 from the Centers for Medicare and Medicaid (CMS) Hospital Compare, Provider of Service, and Medicare Cost Reports files. They then compared the MRSA and CDI standardized infection ratio (SIR) for California acute care hospitals with those in other states.
In 2013, the average SIR in California hospitals was 0.79 for MRSA, compared with 0.94 for hospitals in other states, and the average CDI SIR was 1.01, versus 0.77 for other states. In 2015, 2016, and 2017, California hospitals had 23%, 30%, and 20% increases in MRSA SIRs compared with other states, while the CDI SIR decreased by 20%, but only in 2017.
Although the decrease in CDI SIR was expected because the ASP mandate restricted antibiotic use in California hospitals, the authors of the study say the increase in MRSA SIR may be the result of more proactive identification of antibiotic-resistant pathogens. They also note that the impact of ASPs is likely stronger for gram-negative microorganisms because most of the restricted antibiotics are for gram-negative infections (MRSA is gram-positive).
The authors add that more data on postintervention years are needed to assess the long-term impact of the California mandate and that ASP mandates in other states should be studied.
Oct 1 Infect Control Hosp Epidemiol abstract
Analysis: AMR Action Fund won't fix broken antibiotic market
A pharmaceutical industry effort to fund development of new antibiotics through investment in small companies could buy time for reforms to address the underlying market problems facing antibiotic development but will not fix those problems on its own, according to a new analysis in Open Forum Infectious Diseases.
The AMR Action Fund, launched in June by 20 of the world's largest pharmaceutical companies, aims to invest $1 billion in small antibiotic companies with promising products, with the goal of bringing two to four new antibiotics to market by 2030.
Although many of these large drug makers have abandoned antibiotic development because of the lack of financial return on antibiotics, the hope is that their money and technical assistance can help the smaller companies, which struggle financially, bring innovative new products to market and boost the antibiotic development pipeline.
But the analysis of the AMR Action Fund by clinicians with the University of Pittsburgh Department of Medicine and the VA Pittsburgh Healthcare System suggests that while the fund will provide a financial lifeline to struggling companies, it does not address the biggest problem—the low reimbursement for new antibiotics and the need to de-link reimbursement from numbers of prescriptions.
The analysis also highlights how the fund fails to address three particular issues that have contributed to the financial failure of new antibiotics for carbapenem-resistant bacteria: slow clinical uptake by clinicians; the relatively small number of carbapenem-resistant infections that occur in the United States; and an excess of new agents that aren't superior to current antibiotics.
"The Fund's major weaknesses are that it does not directly address the 3 issues identified in our case study, nor will it fix the broken marketplace," the authors wrote. "Its most important charge will be to buy time to convince governments to enact reimbursement reforms ('pull' incentives) or implement new antibiotic development models."
Sep 30 Open Forum Infect Dis abstract